Deutsche Bank’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-8,985
Closed -$165K 4798
2020
Q4
$165K Buy
8,985
+2,478
+38% +$45.2K ﹤0.01% 3570
2020
Q3
$119K Buy
6,507
+599
+10% +$10.1K ﹤0.01% 3470
2020
Q2
$89K Buy
5,908
+1,863
+46% +$26.6K ﹤0.01% 3501
2020
Q1
$64K Sell
4,045
-246
-6% -$3.98K ﹤0.01% 3434
2019
Q4
$68K Buy
4,291
+871
+25% +$14.5K ﹤0.01% 3792
2019
Q3
$50K Sell
3,420
-5,948
-63% -$80.2K ﹤0.01% 3940
2019
Q2
$152K Sell
9,368
-5,164
-36% -$84.3K ﹤0.01% 3987
2019
Q1
$250K Sell
14,532
-636
-4% -$11.5K ﹤0.01% 3875
2018
Q4
$267K Sell
15,168
-12,864
-46% -$218K ﹤0.01% 3716
2018
Q3
$508K Buy
28,032
+5,834
+26% +$120K ﹤0.01% 3775
2018
Q2
$435K Buy
22,198
+22,167
+71,506% +$415K ﹤0.01% 3919
2018
Q1
$0 Sell
31
-92
-75% -$1.68K ﹤0.01% 5703
2017
Q4
$1K Hold
123
﹤0.01% 4961
2017
Q3
$1K Hold
123
﹤0.01% 4841
2017
Q2
$1K Sell
123
-2,915
-96% -$25.7K ﹤0.01% 4886
2017
Q1
$35K Sell
3,038
-4,316
-59% -$52.4K ﹤0.01% 4339
2016
Q4
$95K Buy
7,354
+5,262
+252% +$70.4K ﹤0.01% 4114
2016
Q3
$30K Buy
2,092
+142
+7% +$2.02K ﹤0.01% 4409
2016
Q2
$23K Buy
1,950
+493
+34% +$7.92K ﹤0.01% 4719
2016
Q1
$26K Sell
1,457
-970
-40% -$16.1K ﹤0.01% 4559
2015
Q4
$51K Sell
2,427
-288
-11% -$6.09K ﹤0.01% 4393
2015
Q3
$45K Buy
2,715
+351
+15% +$8.73K ﹤0.01% 4508
2015
Q2
$88K Sell
2,364
-1,136
-32% -$36.6K ﹤0.01% 4303
2015
Q1
$110K Buy
+3,500
New +$94.6K ﹤0.01% 4084

Deutsche Bank's CBMG Position: Q1 2021 in Review

Deutsche Bank sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 8,985 shares — an estimated $165K sold.

Deutsche Bank first reported a position in CBMG in Q1 2015 and held it in 24 quarters. The position peaked at $508K in Q3 2018. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.

  • Deutsche Bank reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
  • Deutsche Bank sold 8,985 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $165K.
  • Deutsche Bank first reported a position in Cellular Biomedicine Group, Inc. in Q1 2015 and held it in 24 quarters.
  • Deutsche Bank's Cellular Biomedicine Group, Inc. position peaked at $508K in Q3 2018.
  • 0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.

Based on Deutsche Bank's 13F filing for Q1 2021, filed 13 May 2021.